IRLAB communicated that the preclinical assets are proceeding according to their respective preclinical development toxicology and GMP manufacturing plans. IRL757, currently in preclinical development for apathy in neurological disorders, is expected to start move to Ph 1 in YE'23, as previously communicated (2023). IRL942 in cognitive decline, however, is now expected to be ready for Ph 1 in H1'24 (2023). Lastly, IRL117, the chosen drug candidate from the P003 project, is just initiating its preclinical programme in preparation for the tox studies and manufacturing activities in '24 needed to start a Ph 1.
Mesdopetam PD-LIDs trial data in H1'23e
IRLAB announced the analysis of the mesdopetam Ph 2b it is still ongoing. Further data of the trial is expected to be presented at a scientific congress during H1'23e, which we believe it will provide a clearer picture of the results announced in 17 Jan. Based on this, it will be up to Ipsen to decide if it considers the results promising enough to move mesdopetam into Ph 3 clinical development.
Aktuellt
SENASTE
